Minireviews
Copyright ©The Author(s) 2022.
World J Stem Cells. Oct 26, 2022; 14(10): 744-755
Published online Oct 26, 2022. doi: 10.4252/wjsc.v14.i10.744
Table 2 Clinical researches on the treatment of osteoarthritis with stromal vascular fraction
Ref.
Treatment
Study type
Patients
Follow-up time
Outcome assessments
Consequences
OA position/number
Pak et al[41,42] (2016, 2018) SVF + HA + PRPCase report3 patients: 1 male, age: 68; 2 females, age: 60 and 873.5 moFRI, MRI, ROM, VASCartilage repaired showed by MRI; all scores improved
Knee
Fodor et al[43] (2016) SVFPilot study6 patients: 1 male, 5 females, mean age: 5912 moROM, WOMAC, VAS, TUG, MRIAll scores improved, no MRI evidence of cartilage regeneration
NCT02357485Knee/8 OA
Yokota et al[44] (2017) SVFCase report13 patients: 2 males, 11 females, mean age: 74.56 moVAS, JKOM, WOMACAll scores improved
Knee/26 OA
Nguyen et al[45] (2017) AM vs AM + SVF + PRPComparative study30 patients (15 per group: 3 males, 12 females) mean age: 5818 moVAS, Lysholm, WOMAC, MRIAll scores improved compared with AM group; AM + SVF + PRP group had obvious cartilage repair show by MRI
NCT02142842Knee
Michalek et al[46] (2017) SVFCase control multi-centric non-randomized study1128 patients: 596 males, 532 females, median age: 6217.2 moModified KOOS/HOOSKOOS/HOOS improved, most patients gradually improved, obesity and more severe OA healed slowly
Knee and hip/1856 OA
Tantuway et al[47] (2017) SVFCase report101 patients: 41 males, 60 females, age: 29-843-24 moKOOSKOOS and joint function improved, pain relieved, patients could move normally
Knee/201 OA
Russo et al[48,49] (2017, 2018) SVFRetrospective study30 patients: 21 males, 9 females, median age: 4312-36 moLysholm, VAS, IKDC-subjective, KOOS41%, 55%, 55%, 64% of the patients improved in the scores, respectively
Diffuse degenerative keen
Bright et al[50] (2018) SVFCase report1 patient: female, age: 27 3 yrWOMAC, HOOSSymptoms of OA reduced, all scores improved, ankylosing spondylitis, depression, anxiety and fatigue improved
Knee and hip
Barfod et al[51] (2019) SVFProspective cohort study20 patients, mean age: 4912 moKOOSKOOS improved
NCT02697682Knee
Roato et al[52] (2019) SVFCase report20 patients: 9 males, 11 females, mean age: 59.618 moVAS, WOMACPain relieved, scores improved
Knee
Hudetz et al[53] (2019) SVFProspective, non-randomized and single center study20 patients: 15 males, 5 females12 moVAS, WOMAC, KOOSAll scores improved, pain and symptoms relieved for up to a year
Knee
Berman et al[54] (2019) SVFCase report2586 patients2-5 yrQuestionnaire (visual acuity pain scores, sustained improvement in function) Over 80% of patients' pain relieved, joint function improved and maintain 1 yr; outcomes between male and female or between SVF alone and SVF + PRP showed no difference
NCT10953523Knee
Michalek et al[55] (2019) SVFMulticenter case-control study29 patients: 9 males, 20 females, mean age: 83.336 moModified KOOS/HOOSApart from 3 elderly patients died from aging, other patients' pain and weekly dosage of analgesics were reduced, KOOS/HOOS improved
Knee and hip
Yokota et al[56] (2019) ADSC vs SVFRetrospective cohort studyADSC: 42 patients; SVF: 38 patients6 moVAS, KOOSNo major complications occurred, knee joint effusion was more likely to occur in SVF group than ADSC group (SVF 8%, ADSC 2%); VAS and KOOS improved in both groups
Knee/128 OA
Mayoly et al[57] (2019)SVF +PRP Case report3 patients: 1 male, 2 females, mean age: 6212 moVAS, PRWE, DASHAll scores improved
NCT03164122Wrist
Hong et al[58] (2019) SVF vs HADouble-blind randomized self-controlled trial16 patients (with bilateral symptomatic knee OA) one side: SVF, the other side: HA. 3 males, 13 females, mean age: 5212 moVAS, WOMAC, ROM, MRI (MOCART, WORMS) Significant improvement of VAS, WOMAC and ROM in SVF group, but no improvement in HA group; SVF group was superior to HA group in cartilage repair showed by MOCART and WORMS
Knee
Tran et al[59] (2019) SVF + AM vs AMSingle-center, non-randomized, placebo-controlled study33 patients, placebo group (AM): 3 males, 12 females, mean age: 58.2; SVF group (SVF + AM): 5 males, 13 females, mean age: 5924 moVAS, WOMAC, Lysholm, OSVAS, WOMAC of SVF group reduced significantly compared with placebo group, and maintained 24 mo; Lysholm, OS of SVF group improved
Knee
Garza et al[60] (2020)SVFDouble-blinded prospective randomized controlled study39 patients (randomly assigned to high-, low-dose SVF, or placebo at 1:1:1)12 moWOMAC, MRISymptoms and pain relieved by SVF treatment for up to at least 12 mo; changes in WOMAC scores reached statistical significance in the high- and low-dose groups compared to the placebo group; the improvements were dose dependent
NCT02726945Knee
Lapuente et al[61] (2020) SVFRetrospective study50 patients: 28 males, 22 females, age: 50-8912 moLequesne, WOMAC, VASAll scores improved
Knee/100 OA
Tsubosaka et al[62] (2020) SVFCase report57 patients: 41 males, 16 females, mean age: 69.413.7 moROM, WOMAC, VAS, KOOS, MRIWOMAC, VAS and KOOS improved, while no significant difference in hip-knee-ankle angle, T2 mapping values of lateral femur and tibia improved significantly
Knee